Stocks Health care ACAD
NASDAQ · Health careAcadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc brought in $1.1B of revenue over the twelve months to June 30, 2026, up 11.8% from a year earlier. Net income was $380.5M, a net margin of 33.4%. Operating cash flow minus capital spending left $105.1M of free cash flow in fiscal 2025. At June 30, 2026 it held $385M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Acadia Pharmaceuticals Inc does
Acadia Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACAD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.1B | $391M | $2.30 | $105.1M |
| 2024 | $957.8M | $226.5M | $1.36 | $157.2M |
| 2023 | $726.4M | -$61.3M | -$0.37 | $16.7M |
| 2022 | $517.2M | -$216M | -$1.34 | -$114M |
| 2021 | $484.1M | -$167.9M | -$1.05 | -$126.8M |
| 2020 | $441.8M | -$281.6M | -$1.79 | -$143.8M |
Latest SEC filings
What Acadia Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 11, 2026Other event 8-K
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026
- June 10, 2026
- May 29, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 6, 2026
- May 1, 2026
Questions about ACAD
What does Acadia Pharmaceuticals Inc do?
Acadia Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACAD.
Is Acadia Pharmaceuticals Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $380.5M on revenue of $1.1B, a net margin of 33.4%.
How much revenue does Acadia Pharmaceuticals Inc make?
Over the twelve months to June 30, 2026 Acadia Pharmaceuticals Inc reported revenue of $1.1B. That is 11.8% more than a year earlier.
When did Acadia Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 24, 2026.
Similar companies
Follow ACAD
Get an email when Acadia Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow ACAD: get an email when it filesWhere the numbers come from
Financial figures are the values Acadia Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.